RP-1664 is under clinical development by Repare Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RP-1664’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RP-1664 overview

RP-1664 is under development for the treatment of solid tumor, breast cancer, non-small cell lung cancer (NSCLC) and neuroblastoma.. The therapeutic candidate is being developed based on SNIPRx platform, CRISPR-based screening platform. It is administered through oral route. It acts by targeting PLK4.

Repare Therapeutics overview

Repare Therapeutics is a precision oncology company that develops novel therapeutics targeting specific vulnerabilities of tumor cells. The company’s pipeline products include RP-3500 to treat genetically defined cancers, PKMYT1 Inhibitor RP-6306 and DNA Polymerase ? for repairing DNA breaks in homologous recombination deficient (HRD) cells. Repare’s proprietary SNIPRx, a genomic and chemo-genomic synthetic lethal screening platform combines CRISPR-enabled gene editing target discovery technology with high-resolution protein crystallography, computational biology, medicinal chemistry and clinical informatics to generate small molecules for clinical investigation. It operates offices in the US and Canada and a laboratory in Canada. Repare Therapeutics is headquartered in St-Laurent, Quebec, Canada.

For a complete picture of RP-1664’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.